Abstract 3533: Clinical impact of NF-KB activation in diffuse large B cell lymphoma

• Published in: Cancer research (Chicago, Ill.) Ill.), 2013-04, Vol.73 (8_Supplement), p.3533-3533
• Main Authors: Odqvist, Lina, Montes-Moreno, Santiago, Sánchez-Beato, Margarita, Sánchez-Verde, Lydia, Mollejo, Manuela, Young, Ken H., Fresno, Manuel F., Mazorra, Francisco, Ruíz-Marcellán, Carmen, Piris, Miguel A.
• Format: Article
• Language: English
• ISSN: 0008-5472; 1538-7445
• DOI: 10.1158/1538-7445.AM2013-3533

Deregulated nuclear factor KB (NF-KB) activity has been associated with a number of lymphoproliferative diseases, including diffuse large B cell lymphoma (DLBCL), but the importance and consequence of this activation are still not fully understood. In this study, we describe the extent of NF-KB activation in a range of human lymphoma types and observe a frequent concurrent activation of both classical and alternative pathways in DLBCL. The activation of the classical and alternative NF-KB pathways, was present in 34.8% and 29.3% of DLBCL cases respectively, as assessed by nuclear expression of p50 (classical pathway) and p52 (alternative pathway) by immunohistochemistry in a series of 167 samples. Activation of NF-KB was observed in both germinal centre B-cell like (GC) and activated B-cell like (ABC) subtypes, although with a predominance of classical NF-KB in the ABC subtype (41,8% positive cases versus 21,2% in the GC subtype). In our cohort of samples from 167 R-CHOP treated DLBCL patients, excluding cases positive for Epstein-Barr virus, nuclear expression of NF-KB was significantly associated with a superior overall survival (Log Rank p